Asthma News: Breaking Asthma News, Comments and Articles. - Page: 5

06:39 EST 27th February 2015 | BioPortfolio

Asthma News - Page: 5Twitter RSS

Read the latest Asthma News from around the world, updated every five minutes. Breaking stories from leading news and press agencies, bloggers and experts on Asthma.

Search or Follow Our Asthma - Page: 5 News…

If you are looking for more stories, you may wish to search our extensive news archives for relevant stories: Search for More Asthma - Page: 5 News.
You can also follow our Asthma - Page: 5 news stories on Twitter: @asthma_bio

Showing "asthma" News Articles 101 to 125 of 1,100+

Friday 13th February 2015

Interfering RNA in Allergen Challenge Blocks Allergic Asthma

Learn more about the contribution of CD86 on dendritic cells in the reactivation of allergen-specific Th2 cells. Respiratory Research

Regeneron Announces Upcoming 2015 Investor Conference Presentations

TARRYTOWN, N.Y., Feb. 13, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences: 2015 RBC Capital Markets' Global Healthcare Conference at 8:30 a.m. Eastern Time on Tuesday, February 24, 2015               Cowen and Company 35th Ann...

Immune cells commit suicide to prevent allergy

Scientists from the CNRS, INSERM and Université de Limoges, working in the Laboratoire Contrôle de la Réponse Immune B et Lymphoproliférations (CNRS/Université de Limoges) have demonstrated that the production of type E immunoglobulins (IgE) by ...

Thursday 12th February 2015

Puerto Rican Officials Blame Parents of Children with Obesity, Consider Fines

SILVER SPRING, Md., Feb. 12, 2015 /PRNewswire-USNewswire/ -- In an attempt to address the significant problem of childhood obesity in the United States territory, Puerto Rican officials have proposed a $500 - $800 fine for parents whose children have obesity and have not improved after parent-focused education. The legislators supporting the bill under debate say it is intended to improv...

Xencor, Inc. to Host Fourth Quarter and Full Year 2014 Financial Results Webcast and Conference Call

MONROVIA, Calif., Feb. 12, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release fourth quarter and full year 2014 financial results after the market closes on Thursday, February 19, 2015. Xencor m...

Aerocrine: Last Day of Trading in BTA Brought Forward

Regulatory News: The last day for trading in paid subscribed shares (BTA) (ISIN SE0006593885) on Nasdaq Stockholm has been brought forward to February 16, 2015. The new shares created through conversion of the BTAs will commence trading on Nasdaq Stockholm as from February 18, 2015. About Aerocrine Aerocrine AB (STO:AEROB)...

Wednesday 11th February 2015

GSK’s Breo Ellipta: FDA Panel To Weigh Large Safety Study For Asthma Claim

LABA safety issues may come to haunt GlaxoSmithKline as FDA’s Pulmonary-Allergy Drugs and Drug Safety and Risk Management advisory committees will focus on the combination’s product’s safety database and whether an outcomes study is needed for ...

Children Outgrow Prematurity-Linked Increase in Asthma Prescriptions

Premature birth is associated with an increased use of prescription asthma medication through adolescence, but this tendency disappears by young adulthood, according to a Danish National Cohort Study. Reuters Health Information

1st Patient Enrolled in PARI PROVIDE; New Compressor Access Program for Kitabis Pak Patients

RICHMOND, Va., Feb. 11, 2015 /PRNewswire/ -- The first patient has been enrolled in the PARI PROVIDE compressor access program to accompany the launch of Kitabis Pak.  FDA approved Kitabis Pak as a drug and device combination - the first co-packaging of generic tobramycin inhalation solution with a PARI LC PLUS® Nebulizer for patients with cystic fibrosis. "Kitabis Pak makes takin...

Cumberland Pharmaceuticals Announces Pipeline Expansion With Boxaban™ (ifetroban) Oral Capsule

NASHVILLE, Tenn., Feb. 11, 2015 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced an expansion of its pipeline with a new Phase II development program. The Company has initiated the clinical development of Boxaban™ (ifetroban) oral capsule for the treatment of aspirin-exacerbated respiratory disease (AERD). Cumberland has completed manufacturing and received...

Tuesday 10th February 2015

Gerresheimer Achieves All Targets in 2014

DÜSSELDORF, Germany, February 11, 2015 /PRNewswire/ --   Revenues up 1.9% (3.7% organically) to EUR 1,290.0m  Adjusted EBITDA totals EUR 258.5m at constant exchange rates   Earnings per share up 6.6% to EUR 2.11  Proposed dividend of EUR 0.75 per share (prior year: EUR 0.70 per share)  International expansion continues  Gerresheimer AG, on...

Illinois Charter Schools Leave Health and Safety Behind According to Report from Chicago Medical-Legal Partnership for Children

Only 10% of Illinois Health and Safety Laws Explicitly Applicable to Both Charter and District-Run Public Schools Chicago, Illinois (PRWEB) February 10, 2015 A new report, "School Health and Safety For All," from the Chicago Medical-Legal Partnership for Children outlines an incomplete patchwork of health, wellness, and safety regulations within the Illinois school system; compares char...

Health Tip: Coping With Mold Allergy

-- Mold can creep into your home, causing symptoms including sneezing, coughing and watery eyes to those who are allergic. The American Academy of Allergy Asthma & Immunology offers these tips for mold allergy sufferers: When mold counts are...

New population of regulatory T-cells linked to asthma could be used to combat tumours

When the mucosal surfaces in the lungs of healthy people come into contact with allergenic substances, so-called regulatory T cells also known as Treg cells, are activated. These are capable of actively preventing the development of allergies. Howe...

FDA advisers to review COPD drug from Theravance, GSK as asthma treatment

A panel of FDA advisers agreed to review a supplemental new drug application submitted by Theravance and GlaxoSmithKline to u -More- 

Far out: Psychedelic drug prevents asthma development in mice

A psychedelic drug, (R)-DOI, prevents the development of allergic asthma in a mouse model. The effects are potent and effective at a concentration 50-100 times less than would influence behavior. read more

Medical News Today: Asthma development prevented with psychedelic drug in mouse study

Researchers claim that their findings represent a “significant breakthrough” in the study of serotonin, psychiatric drugs and asthma.

Monday 9th February 2015

Study finds psychedelic drug prevents asthma development in mice

Research led by Charles Nichols, PhD, Associate Professor of Pharmacology and Experimental Therapeutics at the LSU Health New Orleans School of Medicine, has found that a psychedelic drug, (R)-DOI, prevents the development of allergic asthma in a mou...

Psychedelic drug prevents asthma development in mice

Researchers have found that a psychedelic drug, (R)-DOI, prevents the development of allergic asthma in a mouse model. The effects are potent and effective at a concentration 50-100 times less than would influence behavior.

FDA advisory committee to review Theravance's BREO ELLIPTA (FF/VI) for asthma

Theravance, announced that on March 19, 2015, the US Food and Drug Administration's Pulmonary-Allergy Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee will discuss the supplemental New Drug Application (NDA) 204275-S001...

Ritter Pharmaceuticals Names Matthew W. Foehr to Its Board of Directors

Ritter Pharmaceuticals, Inc., a privately held pharmaceutical company focused on gastrointestinal disorders, announces the appointment of Matthew W. Foehr to the Company’s Board of Directors. Mr. Foehr is President and Chief Operating Officer of Ligand Pharmaceuticals (NASDAQ: LGND) and his appointment expands Ritter’s Board membership to five Director...

Scientists identify a new population of regulatory T-cells

Discovery improves understanding of the cause of allergic asthma and may serve as an early diagnostic marker / Publication in Nature Immunology

CoLucid Pharmaceuticals Appoints Matthew Dallas as Chief Financial Officer and Treasurer

DURHAM, N.C., Feb. 9, 2015 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., a privately held biopharmaceutical company, announced today the appointment of Matthew Dallas as Chief Financial Officer and Treasurer. Simultaneous with the announcement, CoLucid announced the retirement of Tim C. Gupton, CPA. Tim has been the CFO for CoLucid since its inception, and was also a partner in Hughes P...

Scientists identify new population of regulatory T-cells

When the mucosal surfaces in the lungs of healthy people come into contact with allergenic substances, so-called regulatory T cells also known as Treg cells, are activated. These are capable of actively preventing the development of allergies. Howeve...

Sunday 8th February 2015

LSU Health New Orleans research finds psychedelic drug prevents asthma development in mice

(Louisiana State University Health Sciences Center) Research led by Charles Nichols, Ph.D., Associate Professor of Pharmacology and Experimental Therapeutics at the LSU Health New Orleans School of Medicine, has found that a psychedelic drug, (R)-DOI...


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks